DEF 14A: MiNK Therapeutics Proposes Reverse Stock Split to Maintain Nasdaq Listing

MiNK Therapeutics is seeking stockholder approval for a 1-for-10 reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement.

Summary

• MiNK Therapeutics is holding a special meeting of stockholders on January 17, 2025, to vote on a proposal to amend the company's certificate of incorporation.
• The amendment would authorize a reverse stock split of the company's issued and outstanding common stock at a ratio of 1-for-10.
• As of December 16, 2024, MiNK had 39,630,402 shares of common stock issued and outstanding.
• The primary purpose of the reverse stock split is to increase the per-share price of MiNK's common stock to meet Nasdaq's minimum bid price requirement of $1.00 per share.
• The company received a delisting warning from Nasdaq after its stock price remained below $1.00 for 30 consecutive trading days starting January 11, 2024.
• Nasdaq granted MiNK continued listing subject to demonstrating compliance with the minimum bid price rule by February 10, 2025.
• The reverse stock split will not change the number of authorized shares or the par value of the common stock ($0.00001).
• No fractional shares will be issued; instead, stockholders will receive a cash payment based on the fair market value of the fractional shares.
• Outstanding stock options and restricted stock units will be adjusted to reflect the reverse stock split.
• The board of directors reserves the right to abandon the reverse stock split even if approved by stockholders.

Sentiment

Score: 6

Explanation: The document is primarily factual and procedural, outlining the need for a reverse stock split to maintain Nasdaq listing. While the company expresses optimism that the reverse stock split will help, there's an underlying concern about the company's stock price and compliance with listing requirements. The sentiment is neutral to slightly positive, reflecting a necessary but potentially risky maneuver.

Positives

• Maintaining the Nasdaq listing is expected to support stock liquidity and company recognition.
• The reverse stock split will provide the company with greater flexibility in considering and planning for future potential business needs.
• The reverse stock split will result in additional authorized and unissued shares becoming available for general corporate purposes as the Board may determine from time to time, including for use under its equity compensation plans.

Negatives

• The reverse stock split may not guarantee a sustained increase in the stock price.
• The market price of the common stock will continue to be based, in part, on the company's performance and other factors unrelated to the number of shares outstanding.
• The availability of additional authorized shares for issuance may have the effect of discouraging a merger, tender offer, proxy contest, or other attempt to obtain control of the Company.

Risks

• The company may not be able to maintain compliance with Nasdaq's minimum bid price requirement even after the reverse stock split.
• The market price of the common stock will continue to be based, in part, on the company's performance and other factors unrelated to the number of shares outstanding.
• The availability of additional authorized shares for issuance may have the effect of discouraging a merger, tender offer, proxy contest, or other attempt to obtain control of the Company.

Future Outlook

The company believes a reverse stock split will result in a higher price per share for outstanding shares of our common stock, and therefor will allow us to maintain compliance with Nasdaqs continued listing requirements.

Management Comments

• The Board believes it is in the best interest of the Company to approve the amendment to our Certificate of Incorporation to effect a reverse stock split of the Companys issued and outstanding common stock to give the Company greater flexibility in considering and planning for future potential business needs.
• The Board also believes the amendment to our Certificate of Incorporation is necessary to ensure that we continue to satisfy the requirements for the continued listing of our common stock on the Nasdaq Capital Market (Nasdaq), which we believe helps support and maintain stock liquidity and Company recognition for our stockholders.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. It's a financial maneuver to artificially inflate the stock price to meet listing requirements, but it doesn't fundamentally change the company's value or business prospects.

Comparison to Industry Standards

• Many biotech companies facing similar situations have implemented reverse stock splits.
• For example, companies like Geron Corporation and Ocugen Inc. have previously executed reverse stock splits to maintain Nasdaq compliance.
• The success of a reverse stock split in maintaining compliance and improving investor confidence varies and depends on the company's underlying performance and market conditions.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but their percentage ownership will remain the same.
• The reverse stock split could impact investor confidence and the market price of the stock.
• Employees holding stock options or restricted stock units will see adjustments to their awards.

Next Steps

• Stockholders will vote on the proposed reverse stock split at the Special Meeting on January 17, 2025.
• If approved, the company will file the Certificate of Amendment with the Secretary of State of Delaware.
• The company must demonstrate compliance with Nasdaq's minimum bid price rule by February 10, 2025.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, delisting, common stock, proxy statement, stockholders, INKT, MiNK Therapeutics